263 related articles for article (PubMed ID: 33821975)
1. Emerging therapies for inv(16) AML.
Surapally S; Tenen DG; Pulikkan JA
Blood; 2021 May; 137(19):2579-2584. PubMed ID: 33821975
[TBL] [Abstract][Full Text] [Related]
2. Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.
Castilla LH; Bushweller JH
Adv Exp Med Biol; 2017; 962():229-244. PubMed ID: 28299661
[TBL] [Abstract][Full Text] [Related]
3. Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.
Richter L; Wang Y; Hyde RK
Oncotarget; 2016 Oct; 7(40):66255-66266. PubMed ID: 27542261
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).
Zhao W; Claxton DF; Medeiros LJ; Lu D; Vadhan-Raj S; Kantarjian HM; Nguyen MH; Bueso-Ramos CE
Am J Surg Pathol; 2006 Nov; 30(11):1436-44. PubMed ID: 17063086
[TBL] [Abstract][Full Text] [Related]
5. Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16).
Markus J; Garin MT; Bies J; Galili N; Raza A; Thirman MJ; Le Beau MM; Rowley JD; Liu PP; Wolff L
Cancer Res; 2007 Feb; 67(3):992-1000. PubMed ID: 17283131
[TBL] [Abstract][Full Text] [Related]
6. Cbfbeta reduces Cbfbeta-SMMHC-associated acute myeloid leukemia in mice.
Heilman SA; Kuo YH; Goudswaard CS; Valk PJ; Castilla LH
Cancer Res; 2006 Dec; 66(23):11214-8. PubMed ID: 17145866
[TBL] [Abstract][Full Text] [Related]
7. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
Richter LE; Wang Y; Becker ME; Coburn RA; Williams JT; Amador C; Hyde RK
Mol Cancer Res; 2019 Jun; 17(6):1241-1252. PubMed ID: 30814129
[TBL] [Abstract][Full Text] [Related]
8. Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance.
Zhang L; Nguyen LXT; Chen YC; Wu D; Cook GJ; Hoang DH; Brewer CJ; He X; Dong H; Li S; Li M; Zhao D; Qi J; Hua WK; Cai Q; Carnahan E; Chen W; Wu X; Swiderski P; Rockne RC; Kortylewski M; Li L; Zhang B; Marcucci G; Kuo YH
Nat Commun; 2021 Oct; 12(1):6154. PubMed ID: 34686664
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of adult patients treated for acute myeloid leukemia with inv 16 in Casablanca (Morocco).
Houssou B; Lamchahab M; Massi R; Oukkache B; Quessar A
Bull Cancer; 2018 Jun; 105(6):552-555. PubMed ID: 29735159
[No Abstract] [Full Text] [Related]
10. FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.
Kim HG; Kojima K; Swindle CS; Cotta CV; Huo Y; Reddy V; Klug CA
Blood; 2008 Feb; 111(3):1567-74. PubMed ID: 17967943
[TBL] [Abstract][Full Text] [Related]
11. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
Xiaosu Z; Leqing C; Yazhen Q; Yu W; Xiaohui Z; Lanping X; Xiaojun H; Yingjun C
Ann Hematol; 2019 Jan; 98(1):73-81. PubMed ID: 30159599
[TBL] [Abstract][Full Text] [Related]
12. RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
Zhen T; Cao Y; Ren G; Zhao L; Hyde RK; Lopez G; Feng D; Alemu L; Zhao K; Liu PP
Blood; 2020 Nov; 136(21):2373-2385. PubMed ID: 32929473
[TBL] [Abstract][Full Text] [Related]
13. Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.
Illendula A; Pulikkan JA; Zong H; Grembecka J; Xue L; Sen S; Zhou Y; Boulton A; Kuntimaddi A; Gao Y; Rajewski RA; Guzman ML; Castilla LH; Bushweller JH
Science; 2015 Feb; 347(6223):779-84. PubMed ID: 25678665
[TBL] [Abstract][Full Text] [Related]
14. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
[TBL] [Abstract][Full Text] [Related]
15. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates.
Adya N; Stacy T; Speck NA; Liu PP
Mol Cell Biol; 1998 Dec; 18(12):7432-43. PubMed ID: 9819429
[TBL] [Abstract][Full Text] [Related]
16. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
17. Core-binding factor beta (CBFbeta), but not CBFbeta-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFbeta-deficient embryonic stem cells.
Miller JD; Stacy T; Liu PP; Speck NA
Blood; 2001 Apr; 97(8):2248-56. PubMed ID: 11290585
[TBL] [Abstract][Full Text] [Related]
18. A case with a cytogenetically cryptic variant of the inv(16)(p13q22)/t(16;16)(p13;q22).
Van Obbergh F; Michaux L; Maertens J; Schoemans H; Vandenberghe P
Cancer Genet; 2014 May; 207(5):231-2. PubMed ID: 24972931
[No Abstract] [Full Text] [Related]
19. Core binding factor beta-smooth muscle myosin heavy chain chimeric protein involved in acute myeloid leukemia forms unusual nuclear rod-like structures in transformed NIH 3T3 cells.
Wijmenga C; Gregory PE; Hajra A; Schröck E; Ried T; Eils R; Liu PP; Collins FS
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1630-5. PubMed ID: 8643682
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia with t(16;16) (p13;q22) showing a new CBFB-MYH11 fusion transcript associated with an atypical leukemic blasts morphology.
Albano F; Anelli L; Zagaria A; Coccaro N; Tota G; Impera L; Minervini CF; Cellamare A; Delia M; Minervini A; Casieri P; Specchia G
Hum Pathol; 2014 Mar; 45(3):643-7. PubMed ID: 24342433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]